Emmenegger U - Search Results

1

A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.

Cramarossa G, Lee EK, Sivanathan L, Georgsdottir S, Lien K, Santos KD, Chan K, Emmenegger U. Cramarossa G, et al. Among authors: emmenegger u. Biomark Med. 2014;8(6):893-911. doi: 10.2217/bmm.14.14. Biomark Med. 2014. PMID: 25224945 Review.

2

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.

Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. Emmenegger U, et al. Cancer Res. 2004 Jun 1;64(11):3994-4000. doi: 10.1158/0008-5472.CAN-04-0580. Cancer Res. 2004. PMID: 15173013

3

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Shaked Y, et al. Among authors: emmenegger u. Blood. 2005 Nov 1;106(9):3058-61. doi: 10.1182/blood-2005-04-1422. Epub 2005 Jul 5. Blood. 2005. PMID: 15998832 Free PMC article.

4

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.

Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Shaked Y, et al. Among authors: emmenegger u. Cancer Res. 2005 Aug 15;65(16):7045-51. doi: 10.1158/0008-5472.CAN-05-0765. Cancer Res. 2005. PMID: 16103050

5

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Emmenegger U, et al. Neoplasia. 2011 Jan;13(1):40-8. doi: 10.1593/neo.101174. Neoplasia. 2011. PMID: 21245939 Free PMC article.

6

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Chow A, et al. Among authors: emmenegger u. Invest New Drugs. 2014 Feb;32(1):47-59. doi: 10.1007/s10637-013-9974-3. Epub 2013 Jun 2. Invest New Drugs. 2014. PMID: 23728939

7

Low-dose metronomic chemotherapy: a systematic literature analysis.

Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Lien K, et al. Among authors: emmenegger u. Eur J Cancer. 2013 Nov;49(16):3387-95. doi: 10.1016/j.ejca.2013.06.038. Epub 2013 Jul 20. Eur J Cancer. 2013. PMID: 23880474 Review.

8

In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes.

Sivanathan L, Chow A, Wong A, Hoang VC, Emmenegger U. Sivanathan L, et al. Among authors: emmenegger u. Prostate. 2014 May;74(5):537-46. doi: 10.1002/pros.22774. Epub 2014 Jan 16. Prostate. 2014. PMID: 24435653

9

FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?

Lee EK, Martinez MC, Blakely K, Santos KD, Hoang VC, Chow A, Emmenegger U. Lee EK, et al. Among authors: emmenegger u. Med Hypotheses. 2014 Oct;83(4):482-7. doi: 10.1016/j.mehy.2014.08.005. Epub 2014 Aug 11. Med Hypotheses. 2014. PMID: 25155552

10

High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.

Jamani R, Lee EK, Berry SR, Saluja R, DeAngelis C, Giotis A, Emmenegger U. Jamani R, et al. Among authors: emmenegger u. Eur J Clin Pharmacol. 2016 Nov;72(11):1391-1399. doi: 10.1007/s00228-016-2120-3. Epub 2016 Aug 25. Eur J Clin Pharmacol. 2016. PMID: 27561266

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters